Horizon Therapeutics PLC (NASDAQ:HZNP) insider Jeff Kent sold 3,620 shares of Horizon Therapeutics stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total transaction of $89,196.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Horizon Therapeutics stock traded down $0.24 during midday trading on Friday, hitting $23.88. The company had a trading volume of 1,312,534 shares, compared to its average volume of 1,763,988. The company has a market cap of $4.42 billion, a price-to-earnings ratio of 13.05 and a beta of 0.93. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. Horizon Therapeutics PLC has a 1-year low of $15.92 and a 1-year high of $29.44.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. Horizon Therapeutics’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the company posted $0.03 earnings per share. As a group, research analysts forecast that Horizon Therapeutics PLC will post 1.63 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the stock. JMP Securities lifted their price target on shares of Horizon Therapeutics from $26.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. Mizuho reissued a “neutral” rating and issued a $27.00 price target on shares of Horizon Therapeutics in a research report on Friday, March 1st. Jefferies Financial Group lifted their price target on shares of Horizon Therapeutics to $34.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cowen set a $33.00 price objective on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, February 28th. Finally, BidaskClub upgraded shares of Horizon Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $30.83.
WARNING: “Jeff Kent Sells 3,620 Shares of Horizon Therapeutics PLC (HZNP) Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4364953/jeff-kent-sells-3620-shares-of-horizon-therapeutics-plc-hznp-stock.html.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: Hedge Funds
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.